Presentation is loading. Please wait.

Presentation is loading. Please wait.

Goulnar Kasymjanova, MD, José A

Published byΧάρις Γεωργιάδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Goulnar Kasymjanova, MD, José A"— Presentation transcript:

1 Prognostic Value of the Six-Minute Walk in Advanced Non-small Cell Lung Cancer 
Goulnar Kasymjanova, MD, José A. Correa, PhD, Harvey Kreisman, MD, Esther Dajczman, RN, MSc, Carmela Pepe, MD, Sarah Dobson, MSc, Lucie Lajeunesse, RN, Rajesh Sharma, MD, David Small, MD  Journal of Thoracic Oncology  Volume 4, Issue 5, Pages (May 2009) DOI: /JTO.0b013e31819e77e8 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Prevalence of clinically significant changes in 6MW (postrechemotherapy) after two cycles. The line indicating the cutoff for a clinically significant decline (−54 m) is shown. The change in 6MW of individual patients with freedom from progression (○) and progressive disease (▪) is shown. The rate of disease progression was not statistically different between those who improved/unchanged versus those who declined, p = 0.48. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e31819e77e8) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Survival of patients with different levels of performance during the initial 6MW test. —— Patients who walked >400 m on initial 6MW (n = 35). …… Patients who walked <400 m on initial 6MW (n = 29). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e31819e77e8) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Goulnar Kasymjanova, MD, José A"

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis  Lama Sakr, MD, MSc, FRCPC, David Small,

Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis  Lama Sakr, MD, MSc, FRCPC, David Small,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.
Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival  Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival  Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Similar presentations

Ads by Google